Drug–drug interactions involving antidepressants: focus on desvenlafaxine

Yvette Low,1 Sajita Setia,2 Graca Lima3 1Department of Pharmacy, National University of Singapore, Singapore; 2Medical Affairs, Pfizer Pte. Ltd., Singapore; 3Global Medical Affairs, Asia-Pacific Region, Pfizer, Hong Kong Abstract: Psychiatric and physical conditions often coexist, and there is rob...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Low Y, Setia S, Lima G
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2018
Materias:	desvenlafaxine polypharmacy comorbidities depression pharmacokinetics Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/47a701b3d7a547669d3dfdfec065def1
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:47a701b3d7a547669d3dfdfec065def1
record_format	dspace
spelling	oai:doaj.org-article:47a701b3d7a547669d3dfdfec065def12021-12-02T02:38:17ZDrug–drug interactions involving antidepressants: focus on desvenlafaxine1178-2021https://doaj.org/article/47a701b3d7a547669d3dfdfec065def12018-02-01T00:00:00Zhttps://www.dovepress.com/drug-drug-interactions-involving-antidepressants-focus-on-desvenlafaxi-peer-reviewed-article-NDThttps://doaj.org/toc/1178-2021Yvette Low,1 Sajita Setia,2 Graca Lima3 1Department of Pharmacy, National University of Singapore, Singapore; 2Medical Affairs, Pfizer Pte. Ltd., Singapore; 3Global Medical Affairs, Asia-Pacific Region, Pfizer, Hong Kong Abstract: Psychiatric and physical conditions often coexist, and there is robust evidence that associates the frequency of depression with single and multiple physical conditions. More than half of patients with depression may have at least one chronic physical condition. Therefore, antidepressants are often used in cotherapy with other medications for the management of both psychiatric and chronic physical illnesses. The risk of drug–drug interactions (DDIs) is augmented by complex polypharmacy regimens and extended periods of treatment required, of which possible outcomes range from tolerability issues to lack of efficacy and serious adverse events. Optimal patient outcomes may be achieved through drug selection with minimal potential for DDIs. Desvenlafaxine is a serotonin–norepinephrine reuptake inhibitor approved for the treatment of adults with major depressive disorder. Pharmacokinetic studies of desvenlafaxine have shown a simple metabolic profile unique among antidepressants. This review examines the DDI profiles of antidepressants, particularly desvenlafaxine, in relation to drugs of different therapeutic areas. The summary and comparison of information available is meant to help clinicians in making informed decisions when using desvenlafaxine in patients with depression and comorbid chronic conditions. Keywords: desvenlafaxine, polypharmacy, comorbidities, depression, pharmacokineticsLow YSetia SLima GDove Medical PressarticledesvenlafaxinepolypharmacycomorbiditiesdepressionpharmacokineticsNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol Volume 14, Pp 567-580 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	desvenlafaxine polypharmacy comorbidities depression pharmacokinetics Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	desvenlafaxine polypharmacy comorbidities depression pharmacokinetics Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Low Y Setia S Lima G Drug–drug interactions involving antidepressants: focus on desvenlafaxine
description	Yvette Low,1 Sajita Setia,2 Graca Lima3 1Department of Pharmacy, National University of Singapore, Singapore; 2Medical Affairs, Pfizer Pte. Ltd., Singapore; 3Global Medical Affairs, Asia-Pacific Region, Pfizer, Hong Kong Abstract: Psychiatric and physical conditions often coexist, and there is robust evidence that associates the frequency of depression with single and multiple physical conditions. More than half of patients with depression may have at least one chronic physical condition. Therefore, antidepressants are often used in cotherapy with other medications for the management of both psychiatric and chronic physical illnesses. The risk of drug–drug interactions (DDIs) is augmented by complex polypharmacy regimens and extended periods of treatment required, of which possible outcomes range from tolerability issues to lack of efficacy and serious adverse events. Optimal patient outcomes may be achieved through drug selection with minimal potential for DDIs. Desvenlafaxine is a serotonin–norepinephrine reuptake inhibitor approved for the treatment of adults with major depressive disorder. Pharmacokinetic studies of desvenlafaxine have shown a simple metabolic profile unique among antidepressants. This review examines the DDI profiles of antidepressants, particularly desvenlafaxine, in relation to drugs of different therapeutic areas. The summary and comparison of information available is meant to help clinicians in making informed decisions when using desvenlafaxine in patients with depression and comorbid chronic conditions. Keywords: desvenlafaxine, polypharmacy, comorbidities, depression, pharmacokinetics
format	article
author	Low Y Setia S Lima G
author_facet	Low Y Setia S Lima G
author_sort	Low Y
title	Drug–drug interactions involving antidepressants: focus on desvenlafaxine
title_short	Drug–drug interactions involving antidepressants: focus on desvenlafaxine
title_full	Drug–drug interactions involving antidepressants: focus on desvenlafaxine
title_fullStr	Drug–drug interactions involving antidepressants: focus on desvenlafaxine
title_full_unstemmed	Drug–drug interactions involving antidepressants: focus on desvenlafaxine
title_sort	drug–drug interactions involving antidepressants: focus on desvenlafaxine
publisher	Dove Medical Press
publishDate	2018
url	https://doaj.org/article/47a701b3d7a547669d3dfdfec065def1
work_keys_str_mv	AT lowy drugndashdruginteractionsinvolvingantidepressantsfocusondesvenlafaxine AT setias drugndashdruginteractionsinvolvingantidepressantsfocusondesvenlafaxine AT limag drugndashdruginteractionsinvolvingantidepressantsfocusondesvenlafaxine
_version_	1718402281590751232

Drug&ndash;drug interactions involving antidepressants: focus on desvenlafaxine

Ejemplares similares

Drug–drug interactions involving antidepressants: focus on desvenlafaxine